三维组织药敏法在肿瘤个体化精准医疗中的应用

doi:10.11904/j.issn.1002-3070.2018.03.019

摘要/Abstract

摘要： 目前恶性肿瘤的化疗方案大多采用美国国立综合癌症网络(National comprehensive cancer network,NCCN)临床实践指南推荐的标准化疗方案,因忽略了肿瘤内在固有的异质性,导致有效率低、毒副作用大、费用高等问题。因此,实现肿瘤“个体化精准医疗”是大势所趋。肿瘤患者进行化疗药物敏感性筛查,以期达到个体化精准给药,是“个体化精准医疗”的主要内容之一。三维组织药敏法(Histoculture drug response assay,HDRA)是将手术切除或活检获取的活性肿瘤组织块经体外培养后,进行药物敏感性检测的方法,不仅实验周期短,而且还保持了肿瘤组织的结构、异型性和微环境,与临床一致性较好,是一种比较有前景的肿瘤药敏检测技术。因此,本文就HDRA的发展历程、临床应用以及未来的发展趋势做一综述。

关键词: 三维组织药敏法, 恶性肿瘤, 个性化精准医疗, 化学治疗

Abstract: At present,most chemotherapy schemes for malignant tumors use the standard chemotherapy regimen recommended by the National Comprehensive Cancer Network(NCCN)clinical practice guidelines,because they ignore the inherent heterogeneity of the tumor,resulting in low efficiency,high toxic and side effects,and high costs issues.Therefore,the realization of “individualized and accurate medical care” for cancer is a general trend.The sensitivity screening of chemotherapy drugs for cancer patients to achieve individualized precise drug delivery is one of the main contents of “individualized precision medicine”.The three-dimensional histoculture drug response assay(HDRA)is a method for detecting drug sensitivity after in vitro cultivation of active tumor tissue blocks obtained by surgical resection or biopsy.It not only has a short experimental cycle,but it also maintains the tumor tissue structure,heterogeneity and micro-environment,which have high clinical practice consistency,and it is a relatively promising technique for detecting drug susceptibility.Therefore,this article reviews the development history,clinical application and the future development trend of HDRA.

Key words: HDRA, Malignant tumor, Individualized precision medicine, Chemotherapeutics

中图分类号:

R73-35+1

纪巧, 陈丽(综述), 何远桥(审校). 三维组织药敏法在肿瘤个体化精准医疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 280-284.

JI Qiao, CHEN Li, HE Yuanqiao. Application of drug sensitivity from three-dimensional tissue in individualized precision medical treatment for tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 280-284.

参考文献

1 Chen W,Zheng R,Zhang S,et al.Cancer incidence and mortality in China in 2013:an analysis based on urbanization level[J].Chin J Cancer Res,2017,29(1):1-10.
2 Al-batran SE,Hartmann JT,Hoffhein ZR,et al.Biweekly fluorouracil,leucovorin,oxaliplatin,and docetaxel(FLOT)for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction:a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie[J].Ann Oncology,2008,19(11):1882-1887.
3 Matchettk KB,Lynamlennon N,Watson RW,et al.Advances in precision medicine:tailoring individualized therapies[J].Cancers,2017,9(11):146.
4 Topol EJ.Individualized medicine from prewomb to tomb[J].Cell,2014,157(1):241-253.
5 Collins FS,Harmus H.A new initiative on precision medicine[J].New Engl J Med,2015,372(9):793-795.
6 Hoffman RM.In vitro sensitivity assays in cancer:A review,analysis,and prognosis[J].J Clin Lab Anal,2010,5(2):133-143.
7 Schrag D,Garewal HS,Burstein HJ,et al.American society of clinical oncology technology assessment:chemotherapy sensitivity and resistance assays[J].J Clin Oncol,2004,22(17):3631-3638.
8 Samson DJ,Seidenfeld J,Ziegler K,et al.Chemotherapy sensitivity and resistance assays:a systematic review[J].J Clin Oncol,2004,22(17):3618-3630.
9 Gwak HS,Park HJ,Yoo H,et al.Chemotherapy for malignant gliomas based on histoculture drug response assay:a pilot study[J].J Korean Neurosurg Soc,2011,50(5):426-433.
10 Freeman AE,Hoffman RM.In vivo-like growth of human tumors in vitro[J].Proc Natl Acad Sci U S A,1986,83(8):2694-2698.
11 Vescio RA,Redfern CH,Nelson TJ,et al.In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture[J].Proc Natl Acad Sci U S A,1987,84(14):5029-5033.
12 Uruno T,Masaki C,Akaishi J,et al.Chemosensitivity of anaplastic thyroid cancer based on a histoculture drug response assay[J].Int J Endocrinol,2015,2015:967286.
13 Fujita Y,Hiramatsu M,Kawai M,et al.Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer[J].Oncol Rep,2009,21(2):499.
14 Yoon YS,Kim CW,Roh SA,et al.Applicability of histoculture drug response assays in colorectal cancer chemotherapy[J].Anticancer Res,2012,32(8):3581-35816.
15 Hoffman RM.The three-dimensional question:can clinically relevant tumor drug resistance be measured in vitro?[J].Cancer Metast Rev,1994,13(2):169-173.
16 Carrel A.On the permanent life of tissues outside of the organism[J].J Exp Med,1912,15(5):516-528.
17 Hoffman R.Histoculture and the immunodeficient mouse come to the cancer clinic-rational approaches to individualizing cancer-therapy and new drug-evaluation(review)[J].Int J Oncol,1992,1(4):467-474.
18 Delyon J,Varna M,Feugeas JP,et al.Validation of a preclinical model for assessment of drug efficacy in melanoma[J].Oncotarget,2016,7(11):13069-13081.
19 Colangelo D,Guo HY,Connors KM,et al.Noncolorimetric measurement of cell activity in three-dimensional histoculture using the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide:the pixel image analysis of formazan crystals[J].Anal Biochem,1992,205(1):8-13.
20 Plumb JA.Cell sensitivity assays:the MTT assay[J].Methods Mol Biol,2011,731(88):237-245.
21 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
22 Yoshimasu T,Oura S,Hirai I,et al.Data acquisition for the histoculture drug response assay in lung cancer[J].J Thorac Cardiovasc Surg,2007,133(2):303-308.
23 高隆,霍润辉.肺癌体外药敏试验与临床疗效的相关性[J].医学争鸣,2003,24(23):2203-2205.
24 Yoshimasu T,Ohta F,Oura S,et al.Histoculture drug response assay for gefitinib in non-small-cell lung cancer[J].Gen Thorac Cardiovasc Surg,2009,57(3):138-143.
25 Yoon YS,Kim CW,Roh SA,et al.Development and applicability of integrative tumor response assays for metastatic colorectal cancer[J].Anticancer Res,2017,37(3):1297-1303.
26 Hamashima C.Current issues and future perspectives of gastric cancer screening[J].World J Gastroenterol,2014,20(38):13767-13774.
27 Hoffman RM.The clinical benefit of the histoculture drug response assay[J].Gan To Kagaku Ryoho,2000,27(7):321-322.
28 曲爱兵.恶性肿瘤体外药敏试验方法[J].实用肿瘤学杂志,2001,15(3):238-239.
29 Mehren MV.The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors[J].Curr Opin Oncol,2008,20(4):428-432.
30 Fitzmaurice C,Dicker D,Pain A,et al.The global burden of cancer 2013 global burden of disease cancer collaboration[J].JAMA,2015,1(4):505-527.
31 Tanino H,Oura S,Hoffman RM,et al.Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay[J].Anticancer Res,2001,21(6A):4083-4086.
32 Lang J,Gao L,Guo Y,et al.Comprehensive treatment of squamous cell cancer of head and neck:Chinese expert consensus 2013[J].Future Oncol,2014,10(9):1635-1648.
33 Ho AS,Kraus DH,Ganly I,et al.Decision making in the management of recurrent head and neck cancer[J].Head Neck,2014,36(1):144-151.
34 Singh B,Li R,Xu L,et al.et al.Prediction of survival in patients with head and neck cancer using the histoculture drug response assay[J].Head Neck,2002,24(5):437-442.
35 Chan AT,Leung SF,Ngan RK,et al.Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma[J].J Natl Cancer Inst,2005,97(7):536-539.
36 Kanasugi M,Aoki D,Suzuki N,et al.Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer[J].Int J Gynecol Cancer,2006,16(1):409-415.
37 周辉良,鲁功成,罗义麒,等.组织培养药敏测试法在表浅膀胱肿瘤化疗药敏测试中的应用价值[J].临床泌尿外科杂志,2003,18(4):199-201.
38 Roife D,Kang Y,Li W,et al.Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy[J].Surgery,2017,161(5):1246-1254.
39 袁庶强,周志伟,梁永钜,等.三维培养药敏实验测定的结直肠癌化疗敏感性与多药耐药基因蛋白表达的关系[J].癌症,2009,28(9):932-938.

[1]	李吉, 陈杨, 张茂镕, 杨昭, 唐娴, 文洪梅. 中国常见消化系统恶性肿瘤伤残调整寿命年归因于人口老龄化的比例分析和趋势预测[J]. 实用肿瘤学杂志, 2025, 39(5): 372-380.
[2]	周素霞, 许志华, 郭淑玲, 范宁, 徐莉立. 2014—2021年青海省肿瘤登记地区恶性肿瘤发病与死亡流行趋势分析[J]. 实用肿瘤学杂志, 2025, 39(5): 381-387.
[3]	刘洋, 王颖, 马祥, 宋家宝, 刘大民, 陈丽莉. 2021年辽宁省营口市城市居民恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2025, 39(5): 400-404.
[4]	代晓泽, 马玉霞, 李雨婷, 齐笑晴, 祝天岑, 穆慧娟, 刘辉. 2014—2020年辽宁省阜新市城市居民恶性肿瘤发病与死亡流行趋势分析[J]. 实用肿瘤学杂志, 2025, 39(4): 278-283.
[5]	祝天岑, 礼彦侠, 任方晗, 代晓泽, 刘洋, 穆慧娟. 2021年辽宁省肿瘤登记地区恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2025, 39(4): 294-300.
[6]	李吉, 张茂镕, 杨昭, 文洪梅, 伍福仙, 李云涛. 2020年云南省昆明市肿瘤登记地区恶性肿瘤发病和死亡特征及2016—2020年趋势分析[J]. 实用肿瘤学杂志, 2025, 39(3): 169-176.
[7]	文小焱, 陈俐. 2010年和2020年四川省30岁及以上人群恶性肿瘤疾病负担比较分析[J]. 实用肿瘤学杂志, 2025, 39(1): 1-6.
[8]	陈茂森, 陈杨, 石青萍, 邵英, 唐娴, 任思颖, 文洪梅. 2020年云南省恶性肿瘤发病和死亡分析[J]. 实用肿瘤学杂志, 2024, 38(5): 283-288.
[9]	苏锋, 梁磊, 邓英, 张同蕾, 王艳平. 2016—2020年陕西省安康市恶性肿瘤流行特征和变化趋势分析[J]. 实用肿瘤学杂志, 2024, 38(5): 300-305.
[10]	何佳颖, 朱津丽, 贾凯旋, 杨佩颖. IFN-γ在肿瘤免疫检查点抑制剂治疗中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 330-335.
[11]	刘丽莉, 张雪云, 张雷. 2020—2022年第一师阿拉尔市恶性肿瘤发病分析[J]. 实用肿瘤学杂志, 2024, 38(4): 246-253.
[12]	钟女娟, 马晶昱, 许志达. 2019年福建省福清市恶性肿瘤发病与死亡情况及2015—2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(1): 1-6.
[13]	程锦, 王玮. 维甲酸诱导蛋白在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 502-506.
[14]	赵世博, 陈永峰, 黎惠怡, 符爱珍. Agrin参与恶性肿瘤发生发展的研究现状[J]. 实用肿瘤学杂志, 2023, 37(6): 507-512.
[15]	宋述铭, 李改琴, 张黎峰, 许凯, 毛雯靖, 张光辉. 新疆医科大学附属肿瘤医院2010—2020年恶性肿瘤住院患者流行病学分析[J]. 实用肿瘤学杂志, 2023, 37(5): 389-394.